Karnofsky-Adapted Chemotherapy of Non Small Cell Lung Cancer (NSCLC) With Ifosfamide/Mitomycin C/Vindesine

Journal of Cancer Research and Clinical Oncology - Germany
doi 10.1007/bf02579914
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Ifosfamide/Vindesine Chemotherapy in Primarily Resistant or Relapsed Small Cell Lung Cancer

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
1986English

Ifosfamide in Patients With Recurrent Non Small Cell Lung Cancer

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
1986English

Pilot Study of Alternating Radiotherapy and Three-Drug Combined Chemotherapy Consisting of Ifosfamide, Cisplatin and Vindesine in Localized Inoperable Non-Small Cell Lung Cancer.

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
1993English

A Phase II Trial of Midtreatment PET-CT Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer (NSCLC)

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

PCN37 Cost-Minimization Analysis of Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (NSCLC)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Cisplatin, Vindesine, and Concomitant Radiation Therapy for Unresectable Non-Small Cell Lung Cancer.

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
1991English

Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)

Open Access Journal of Oncology and Medicine
2018English

Palliative Chemotherapy for Advanced Non-Small Cell Lung Cancer

BMJ
1994English

PCN134 Patient Preferences for Non-Small Cell Lung Cancer (NSCLC) Treatments

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy